Pfizer's Vepdegestrant Shows Mixed Results in Crucial Breast Cancer Trial

Pfizer Inc. has recently announced the results of its key clinical trial for Vepdegestrant, a drug aimed at treating hormone receptor-positive breast cancer. The findings indicate a mixed response in the effectiveness of the medication, presenting both potential and limits in its application for patients battling this challenging form of cancer.

Continue reading